The Hollings Cancer Center Clinical Trials Office (HCC-CTO) provides clinical, regulatory and administrative research services for more than 60 principal investigators. At any one time, the HCC-CTO manages approximately 475 trials - 200 active enrolling trials, 200 closed-to-accrual trials with patients in follow-up, and 75 pending trials in the approval process.
The HCC-CTO has demonstrated success in clinical trial management. Utilizing our local MUSC Institutional Review Board, the average turnaround time for activating a new study from the point of site selection is 93 days. Our annual rate of therapeutic clinical trial enrollment is 12.4 percent of new cancer patients with 26 percent representing minority populations.
The HCC-CTO participates in Phase I, II, and III clinical trials originating from the NCI and the National Clinical Trials Network, selected pharmaceutical-sponsored trials, and investigator-initiated studies. We have capabilities for conducting Phase I trials and managing multicenter studies.
To learn more about the site capabilities of the Hollings Cancer Center Clinical Trials Office, please contact:
Carolyn D. Britten, MD
Associate Director of Clinical Investigations
David T. Marshall, MD
Deputy Associate Director of Clinical Investigations